
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

High blood pressure reprograms immune system
German scientists headed by Suphansa Sawamiphak from MDC Berlin have discovered in a zebrafish and mouse model of salt-induced hypertension that...

Carbios SAS set to licence and expand PET recycling
Carbios SAS has announced "excellent outputs" from its demonstration plant in Clermont-Ferrand and its advanced engineering study for the...

Ariceum Therapeutics extends Series A to €47.75m
The Series A financing was co-led by new investors Andera Partners and Earlybird Venture Capital. Existing investor Pureos Bioventures doubled its...

VectivBio taken over in $1bn acquisition
VectivBio Holding AG has entered into a acquisition agreement with Ironwood Pharmaceuticals Inc. Ironwood will launch a tender offer to buy...

Forbion raises €1.35bn across two funds
Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up...